Pluri Inc.: insider trades · United States · SEC (Form 4)

About Pluri Inc.

Pluri Inc. is a U.S.-listed biotechnology company trading on the NASDAQ under the ticker PLUR. It is incorporated in the United States, while its main operational base and research footprint are in Haifa, Israel, giving the company an international operating profile. Founded in 2003, Pluri has built its business around a proprietary 3D cell-expansion platform designed to grow cells at scale in a standardized, reproducible, and potentially cost-efficient way. For investors, the company is best viewed as a platform-driven biotech rather than a conventional single-product drug developer: Pluri aims to apply one core cell-engineering capability across several commercial verticals. Historically, Pluri’s core focus has been regenerative medicine and cell therapy. The company develops allogeneic, placenta-derived product candidates and describes a pipeline aimed at major unmet medical needs in areas such as vascular disease, inflammation-related disorders, muscle injuries, and hematological conditions. A key element of its strategy is an in-house GMP manufacturing facility, which supports process control, product consistency, and eventual scale-up. In cell therapy, manufacturing know-how is often as important as the scientific concept itself, so this operational asset is strategically meaningful. Pluri has also broadened its scope beyond healthcare into adjacent markets through venture-building and strategic partnerships. The company has initiatives in food-tech and agtech, including cultivated cacao through Kokomodo and cultivated meat-related activity through Ever After Foods. This diversification potentially expands the addressable market and creates additional monetization paths for the same core technology, but it also increases execution risk and capital demands. Competitively, Pluri’s value proposition rests on three pillars: proprietary intellectual property, scalable cell-production capabilities, and the ability to form partnerships that convert a technology platform into commercial opportunities. Geographically, Pluri combines Israeli R&D depth with access to U.S. capital markets through NASDAQ. Recent developments have been important for investors following the name. In 2025 and 2026, the company highlighted new patent progress, including patent protection in China for its 3D immune cell expansion and activation technology, and it announced a $2.5 million additional investment from an entity beneficially owned by Chairman Alejandro Weinstein in March 2026. In January 2025, Pluri also disclosed a $6.5 million strategic investment and the acquisition of a majority stake in Kokomodo. Taken together, these updates point to a company actively trying to strengthen its balance sheet, defend its intellectual property, and build optionality across biotech and adjacent cell-based industries in the United States and abroad.